Delivering on the promise of cancer biomarkers in the clinic

Article Type

Changed

Thu, 12/15/2022 - 18:07

Display Headline

Author(s)

Cancer is still the second leading cause of death in the United States and earlier diagnosis and effective therapies remain the holy grail of research paradigms. Cancer biomarkers have emerged as an invaluable tool in the achievement of this goal. Technological advancements and greater understanding of the molecular mechanisms of cancer have transformed biomarker research from an observational byproduct of cancer research into a biomedical research field in its own right. Despite the explosion of biomarker discovery over the last decade, few have been translated into clinical use. Here we discuss the current state of biomarker development and the challenges that have tempered their clinical potential.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_Oct_2014_381_de_Lartigue.pdf

Issue

The Journal of Community and Supportive Oncology - 12(10)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Breast Cancer ICYMI

Topics

Breast Cancer

Patient & Survivor Care

Page Number

381-388

Legacy Keywords

biomarkers, cancer, diagnostic markers, prognostic markers

Sections

Author(s)

Author(s)

Article PDF

JCSO_Oct_2014_381_de_Lartigue.pdf

Article PDF

JCSO_Oct_2014_381_de_Lartigue.pdf

Cancer is still the second leading cause of death in the United States and earlier diagnosis and effective therapies remain the holy grail of research paradigms. Cancer biomarkers have emerged as an invaluable tool in the achievement of this goal. Technological advancements and greater understanding of the molecular mechanisms of cancer have transformed biomarker research from an observational byproduct of cancer research into a biomedical research field in its own right. Despite the explosion of biomarker discovery over the last decade, few have been translated into clinical use. Here we discuss the current state of biomarker development and the challenges that have tempered their clinical potential.

Click on the PDF icon at the top of this introduction to read the full article.

Cancer is still the second leading cause of death in the United States and earlier diagnosis and effective therapies remain the holy grail of research paradigms. Cancer biomarkers have emerged as an invaluable tool in the achievement of this goal. Technological advancements and greater understanding of the molecular mechanisms of cancer have transformed biomarker research from an observational byproduct of cancer research into a biomedical research field in its own right. Despite the explosion of biomarker discovery over the last decade, few have been translated into clinical use. Here we discuss the current state of biomarker development and the challenges that have tempered their clinical potential.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 12(10)

Issue

The Journal of Community and Supportive Oncology - 12(10)

Page Number

381-388

Page Number

381-388

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology